Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Perindopril and chronic heart failure].

J P Bounhoure1

  • 1Service de cardiologie, hôpital de Rangueil, Toulouse.

Archives Des Maladies Du Coeur Et Des Vaisseaux
|December 1, 1991
PubMed
Summary

Perindopril significantly improved exercise capacity and clinical scores in patients with cardiac failure. This treatment demonstrated sustained hemodynamic benefits and prevented cardiac decompensation compared to placebo.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Takotsubo or stress cardiomyopathy.

Cardiovascular psychiatry and neurology·2012
Same author

[Influence of sex on the prognosis of high risk acute coronary syndromes treated by early angioplasty].

Archives des maladies du coeur et des vaisseaux·2005
Same author

[Prognosis scores to help revascularization for ischemic heart failure].

Annales de cardiologie et d'angeiologie·2004
Same author

[Evaluation of arrhythmic risk in coronary insufficiency].

Annales de cardiologie et d'angeiologie·2003
Same author

[Effects of bradykinin in the cardiovascular effects of angiotensin-converting enzyme inhibitors].

Archives des maladies du coeur et des vaisseaux·2002
Same author

Rehabilitation of patients with congestive heart failure with or without beta-blockade therapy.

Journal of cardiac failure·2001

Area of Science:

  • Cardiology
  • Pharmacology

Background:

  • Cardiac failure management often involves addressing hemodynamic abnormalities.
  • Perindopril has demonstrated positive hemodynamic effects in patients with cardiac failure.

Purpose of the Study:

  • To evaluate the efficacy and safety of perindopril in patients with New York Heart Association (NYHA) Stage II and III cardiac failure.
  • To assess the impact of perindopril on clinical status, exercise capacity, and hemodynamic parameters.

Main Methods:

  • A 3-month, randomized, double-blind, placebo-controlled multicenter trial involving 125 patients.
  • Patients received perindopril (2 or 4 mg) or placebo, with efficacy assessed using NYHA classification, clinical severity scores, exercise stress tests, and cardiothoracic ratio.

Main Results:

  • Perindopril significantly improved clinical scores and exercise capacity (treadmill duration: 778s vs. 544s).
  • No cardiac decompensation (NYHA Stage IV) occurred in the perindopril group, versus 3 cases in the placebo group.
  • Perindopril showed sustained hemodynamic improvements without significant adverse effects on renal function.

Conclusions:

  • Perindopril is effective and safe for managing NYHA Stage II and III cardiac failure.
  • Perindopril improves patient outcomes, exercise tolerance, and prevents worsening of heart failure.
  • Sustained hemodynamic benefits and a favorable safety profile support the use of perindopril in cardiac failure therapy.

Related Experiment Videos